NAUT Stock Overview
A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nautilus Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.92 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$2.19 |
| Beta | 1.02 |
| 11 Month Change | 31.53% |
| 3 Month Change | 17.27% |
| 1 Year Change | -4.89% |
| 33 Year Change | -62.76% |
| 5 Year Change | n/a |
| Change since IPO | -72.03% |
Recent News & Updates
Recent updates
We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate
Jul 27
We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth
Feb 16Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In Growth
Oct 22We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate
May 25We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth
Feb 17Nautilus Biotechnology Q2 2022 Earnings Preview
Aug 01The Take On Nautilus Biotechnology
Jan 17Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry Point
Jan 07Nautilus Biotechnology: Tapping The Potential Of The Human Proteome
Aug 30Shareholder Returns
| NAUT | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 11.9% | 9.2% | -0.6% |
| 1Y | -4.9% | 0.9% | 17.3% |
Return vs Industry: NAUT underperformed the US Life Sciences industry which returned -0.8% over the past year.
Return vs Market: NAUT underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| NAUT volatility | |
|---|---|
| NAUT Average Weekly Movement | 8.1% |
| Life Sciences Industry Average Movement | 7.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NAUT has not had significant price volatility in the past 3 months.
Volatility Over Time: NAUT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 163 | Sujal Patel | www.nautilus.bio |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system.
Nautilus Biotechnology, Inc. Fundamentals Summary
| NAUT fundamental statistics | |
|---|---|
| Market cap | US$360.76m |
| Earnings (TTM) | -US$67.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs NAUT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAUT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$67.44m |
| Earnings | -US$67.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NAUT perform over the long term?
See historical performance and comparison